<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333891</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-151010</org_study_id>
    <nct_id>NCT01333891</nct_id>
  </id_info>
  <brief_title>Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure</brief_title>
  <official_title>Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related macular degeneration (AMD) and glaucoma are among the leading causes of blindness
      in the western world. Elevated intraocular pressure (IOP) is a well known major risk factor
      for glaucoma. In addition, there is growing evidence that vascular factors, including
      arterial hypertension and hypotension, may play a role in the pathogenesis of AMD and
      glaucoma. To gain more insight into these mechanisms in humans is the primary goal of the
      present study.

      Optical coherence tomography (OCT) delivers three dimensional, volumetric reflectivity
      information through transparent media in vivo. Moreover, the images show a high choroidal
      penetration and a resolution comparable to an histologic examination when infrared light
      sources are used. Because of its non-invasive character, OCT provides an ideal method for
      diagnosis and monitoring of retinal and choroidal abnormalities.

      The present study aims to investigate whether choroidal thickness is temporarily altered by
      changes in IOP or systemic hemodynamic parameters. IOP will be increased by the use of a
      suction cup technique, mean arterial blood pressure will be altered by intravenously
      administered Phenylephrine or Sodium-Nitroprusside.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Choroidal thickness</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic/diastolic blood pressure (non-invasive)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suction Cup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>suction force of 25, 50, 75, and 100 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes</description>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Suction Cup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium-Nitroprusside</intervention_name>
    <description>Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes</description>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Suction Cup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suction Cup</intervention_name>
    <description>experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH</description>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Suction Cup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann applanation tonometer</intervention_name>
    <description>intraocular pressure measurements</description>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Suction Cup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1060nm Optical coherence tomography</intervention_name>
    <description>Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness</description>
    <arm_group_label>Sodium-Nitroprusside</arm_group_label>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_label>Suction Cup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 18 and 35 years, nonsmokers

          -  Men and women will be included in equal parts

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal findings in the laboratory testings unless the investigator considers an
             abnormality to be clinically irrelevant

          -  Normal ophthalmic findings, ametropia less than 1 diopter

        Exclusion Criteria:

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug (except oral contraceptives)

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Blood donation during the previous 3 weeks History of hypersensitivity to the trial
             drugs or to drugs with a similar chemical structure

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with distribution, metabolism or excretion of study drugs

          -  History of migraine

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhöfer, MD, PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. Priv. Doz. Dr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

